Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABG-TIME: Timing of CABG after Ticagrelor
NCT02627521Phase 4Unknown
- Sponsor
- Unity Health Toronto
- Start
- Jul 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (2 arms), sponsored by Unity Health Toronto. Primary endpoint: Length of hospital stay at 30 days. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02627521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02627521.